Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
Alyssa A TooropSamantha NoteboomMartijn D SteenwijkJob W GravendeelBas JasperseFrederik BarkhofEva M M StrijbisTheo RispensMenno Michiel SchoonheimZoé Léonie Elise van KempenJoep KillesteinPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
We found no clear evidence that EID compared to SID or lower natalizumab drug concentrations have a negative impact on the development of brain atrophy over time.